Trial results

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

NCT06109311 on ClinicalTrials.gov · last registry update 2025-10-20

Finished 15 September 2025, after enrolling 546 people. Primary outcome, as filed: Orforglipron Dose 1, 2: Change from Baseline in Hemoglobin A1c (HbA1c). orforglipron is approved in the US, but not for type 2 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

COMPLETED

Phase

P3

Drug

orforglipron

Foundayo

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

546

Started

2023-11-10

Primary completion

2025-09-15 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Orforglipron Dose 1, 2: Change from Baseline in Hemoglobin A1c (HbA1c)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.